Market News AIOpen the app

Evotec won a $2.9 million grant from the Gates Foundation to improve drug safety tests with human stem cells.

DealRead the original at prnewswire.com
Good for EVO

Evotec's $2.9 million grant funds 3 more years of human-cell research for early drug safety checks, supporting its research tools. The report describes continued work, not proven improvements in drug outcomes.

EVO · Evotec SE

AI read · Good for EVO

The AI's read

The funding gives Evotec more support for work on early drug safety checks. Its human-cell models aim to spot risks sooner and make lab findings more useful for people. The report describes continued research, not proof that the tools have improved drug results.

Get alerts for EVO

Follow Evotec SE (EVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EVO
Free on the App Store and Google Play, or on the web.